Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
IPO Year: 2000
Exchange: NYSE
Website: criver.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2026 | $219.00 | Hold → Outperform | CLSA |
| 4/14/2026 | $215.00 | Outperform | RBC Capital Mkts |
| 12/15/2025 | $225.00 | Neutral → Buy | BofA Securities |
| 11/17/2025 | Hold → Buy | Argus | |
| 11/6/2025 | $199.00 | Neutral → Outperform | Robert W. Baird |
| 10/6/2025 | Mkt Perform → Outperform | William Blair | |
| 10/2/2025 | $195.00 | Equal Weight → Overweight | Barclays |
| 9/9/2025 | $195.00 | Hold → Buy | Jefferies |
| 7/9/2025 | $200.00 | Neutral → Buy | Citigroup |
| 5/23/2025 | $182.00 | Neutral → Buy | Redburn Atlantic |
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
S-8 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SCHEDULE 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
DEF 14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
CLSA upgraded Charles River from Hold to Outperform and set a new price target of $219.00
RBC Capital Mkts initiated coverage of Charles River with a rating of Outperform and set a new price target of $215.00
BofA Securities upgraded Charles River from Neutral to Buy and set a new price target of $225.00
Argus upgraded Charles River from Hold to Buy
Robert W. Baird upgraded Charles River from Neutral to Outperform and set a new price target of $199.00
William Blair upgraded Charles River from Mkt Perform to Outperform
Barclays upgraded Charles River from Equal Weight to Overweight and set a new price target of $195.00
Jefferies upgraded Charles River from Hold to Buy and set a new price target of $195.00
Citigroup upgraded Charles River from Neutral to Buy and set a new price target of $200.00
Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
Fastest customizable press release news feed in the world
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for
Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. This press release
Charles River Laboratories International, Inc. (NYSE:CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is committed to cutting at least one week from standard pathology timelines while maintaining Good Laboratory Practice (GLP) rigor and regulatory readiness. These efficiency gains are driven by the combination of a fully integrated histology
– Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200 Million of Common Stock in First Quarter of 2026 – – Completed the Divestiture of the CDMO and Cell Solutions Businesses – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2026. For the quarter, revenue was $995.8 million, an increase of 1.2% from $984.2 million in the first quarter of 2025. The impact of foreign currency translation increased reported revenue by 2.8%, while a divestiture reduced rep
As the first commercial provider to deliver in vitro fertility services for rat models, Company demonstrates commitment to the 3Rs Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity ac
Peer-reviewed evidence supports the use of Virtual Control Groups in nonclinical toxicology studies Charles River Laboratories International, Inc. (NYSE:CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoints. There was 100 percent concordance in the No Observed Adverse Effect Level (NOAEL) across all studies, and although there was some m
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate th
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." Through this collaboration, Cha
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, April 6, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on April 6thEquities rise Monday morning after a report indicates a push towards a ceasefire with Iran.The NYSE is partnering with leading AI conference HumanX at the Moscone Center in San Francisco this week and will have Ashley Mastronardi on the ground speaking to those transforming the space.James Foster, Chairman, President,
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 9:50 a.m. ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presenta
Live finance-specific insights
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate th
– Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi
– Third-Quarter Revenue of $1.00 Billion – – Third-Quarter GAAP Earnings per Share of $1.10 and Non-GAAP Earnings per Share of $2.43 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.3%, and the divestiture of a small Safety Assessment site in 2024 reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 1.6% on an organic basis. On a segment basis, lower revenue in the Discovery
Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2025 financial results on Wednesday, November 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 5th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe a
– Michael G. Knell, Corporate Senior Vice President & Chief Accounting Officer, Appointed Interim CFO by the Board of Directors – – Company Reaffirms 2025 Revenue and Non-GAAP EPS Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer (CFO), has resigned from her role, effective September 29, 2025, to pursue another opportunity. Following Ms. Pease's departure, Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, will serve as interim CFO until a successor is named. The Company has commenced a comprehensive search to identify its next CFO. James
– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.2%. Excluding this impact, revenue declined 0.5% on an organic basis. On a segment basis, an organic revenue decline in the Discovery and Safety Assessment (DSA) segment was partially offset by organic revenue growth
Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
– First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate the
Live Leadership Updates
Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre
– Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology researchCharles River to make an equity investment in Aitia as part of the agreementWILMINGTON, Mass. and SOMERVILLE, Mass., Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. This press release features multimedia. View the full release here: https://www.bu
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River's Board of Directors from 2013 through 2018. Dr. Thompson's extensive scientific expertise in the fields of immuno-oncology and translational and precision medicine, together with his healthcare business leadership experience, will provide a unique contribution of knowledge and guidance to Charles River's Board. As a member of the Board, he will serve on the Science and Technology and Strategic Plannin
This live feed shows all institutional transactions in real time.
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)